| Name | Title | Contact Details |
|---|
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
The START Center offers some of the most sophisticated treatment options available in South Texas along with the world’s largest and most active Phase I clinical trials program. The START Center also offers the Inspiritas Spa and Wellness Center whic...
Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of “precision genetic medicines,” combining precision targeting of the genome with precision control of editing outcomes. Our dream is to provide life-long cures for patients suffering from serious diseases. The Beam Team Is: • A community of fearless innovators • Rigorous and honest in our research • Listening with open minds • Committed to each other
Harvard Medtech`s mission is to solve pain and related afflictions by providing unmatched Tele-PainCare™ solutions that promote safe, effective healing holistically and organically in conjunction with, or preferably in lieu of, surgery and prescription pain medications. Our Vx Pain Relief Program uniquely integrates state-of-the-art Virtual Reality Therapy with Behavioral Health Clinicians, who regularly provide psychological and social interventions by telephone to patients in the comfort of their homes while keeping the prescribing physician apprised of the patient`s progress. Our FDA-registered, clinically validated, whole-person approach to delivering safe, effective, at-home care yields more complete, convenient, timely and affordable relief of pain, depression, anxiety and related afflictions while requiring zero investment by the prescribing physician.
Curie Therapeutics is a fully integrated, next-generation radiopharmaceuticals company focused on pioneering a new class of targeted radiopharmaceuticals that are both safe and effective. Curie`s radiopharmaceuticals are composed of rationally designed conjugates against carefully selected biological targets, to deliver alpha and beta-emitting radionuclide payloads. Curie`s mission is to revolutionize the use of radiomedicines in cancer.